Trials / Completed
CompletedNCT04155918
Phase 2a Study of AR882 Alone and in Combination With Febuxostat or Allopurinol in Gout Patients
A Phase 2a, Open-Label Study to Evaluate the Safety and Efficacy of AR882 Administered Alone or in Combination With Febuxostat or Allopurinol in Gout Patients
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 30 (actual)
- Sponsor
- Arthrosi Therapeutics · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The study is designed to evaluate the PK/PD, safety and tolerability of AR882 alone or in combination with febuxostat or allopurinol when administered to gout patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Group 1: AR882 Alone and in Combination with Febuxostat (FBX) | AR882 + Febuxostat, AR882 alone, Febuxostat alone |
| DRUG | Group 2: AR882 Alone and in Combination with Allopurinol (ALLO) | AR882 + Allopurinol, AR882 alone, Allopurinol alone |
Timeline
- Start date
- 2020-02-03
- Primary completion
- 2020-09-03
- Completion
- 2020-09-03
- First posted
- 2019-11-07
- Last updated
- 2020-11-19
Locations
1 site across 1 country: New Zealand
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04155918. Inclusion in this directory is not an endorsement.